Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...

May 12 (Reuters) - Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised ...

Isomorphic Labs, launched in 2021 with Google DeepMind, unveiled its newest joint AI offering AlphaFold 3, an AI model that was developed by Isomorphic Labs and Google DeepMind. According to ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /CNW/ -- Isomorphic ...

The proceeds will be used to accelerate Isomorphic Labs’ pipeline of therapeutic programmes and further develop its IsoDDE AI ...

Alphabet Inc.’s Isomorphic Labs raised $2.1 billion in its second round of outside capital, with new support from sovereign wealth funds, as it seeks to make artificial intelligence-designed drugs a ...

What do weapons and drug discovery have in common? Over the last 24 hours, billions of dollars and a lead investor.

Isomorphic Labs, an AI drug discovery and development company, raised $2.1 billion in a Series B funding round led by Thrive Capital. The raise was also backed by existing investors Alphabet and GV ...

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...

Isomorphic previously raised $600 million in external funding last year, which was also led by NYC’s Thrive Capital.

Isomorphic Labs secures $2.1 billion in funding to accelerate its AI-powered drug discovery engine and scale pharmaceutical ...